Last reviewed · How we verify
Vericiguat tablet
Vericiguat tablet is a Small molecule drug developed by Khawaja Danish Ali. It is currently in Phase 2 development. Also known as: MK-1242.
Vericiguat is a small molecule that activates soluble guanylate cyclase, a molecular target. It is being studied for various conditions, including heart failure, coronary microvascular dysfunction, and metabolic syndrome, among others.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Vericiguat tablet |
|---|---|
| Also known as | MK-1242 |
| Sponsor | Khawaja Danish Ali |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) (PHASE2, PHASE3)
- Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial (PHASE1)
- Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome (PHASE2)
- Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction (PHASE2)
- A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis (NA)
- A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction (PHASE2)
- COgnitioN With VERiciGuat Evaluation in Heart Failure (PHASE2)
- Vericiguat for Heart Failure With Reduced Ejection Fraction After Myocardial Infarction
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vericiguat tablet CI brief — competitive landscape report
- Vericiguat tablet updates RSS · CI watch RSS
- Khawaja Danish Ali portfolio CI
Frequently asked questions about Vericiguat tablet
What is Vericiguat tablet?
Who makes Vericiguat tablet?
Is Vericiguat tablet also known as anything else?
What development phase is Vericiguat tablet in?
Related
- Manufacturer: Khawaja Danish Ali — full pipeline
- Also known as: MK-1242
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing